Amprius Technologies, Inc. (AMPX-WT)
Income Statement
Consolidated Statement of Income
AMPRIUS TECHNOLOGIES, INC. (AMPX.W)
Year Ended (In thousands, except shares in actual amounts and per share data)
| Dec 31, 2025 | Dec 31, 2024 | |
|---|---|---|
| Revenue | $73,011 | $24,167 |
| Cost of revenue | $64,747 | $42,497 |
| Gross profit (loss) | $8,264 | $(18,330) |
| Research and development | $9,430 | $7,344 |
| Selling, general and administrative | $22,956 | $18,726 |
| Impairment and other | $22,524 | $1,862 |
| Total operating expenses | $54,910 | $27,932 |
| Loss from operations | (46,646) | (46,262) |
| Interest income and other, net | $2,622 | $1,591 |
| Total other income, net | $2,622 | $1,591 |
| Net loss | $(44,024) | $(44,671) |
| Weighted-average common shares outstanding, basic (in shares) | 124,639,991 | 101,872,347 |
| Weighted-average common shares outstanding, diluted (in shares) | 124,639,991 | 101,872,347 |
| Net loss per share of common stock, basic (in dollars per share) | -0.35 | -0.45 |
| Net loss per share of common stock, diluted (in dollars per share) | -0.35 | -0.45 |
Balance Sheet
Consolidated Balance Sheets
AMPRIUS TECHNOLOGIES, INC. (AMPX.W)
As of December 31, 2025 and December 31, 2024 (In thousands, except shares and per share data)
| Dec 31, 2025 | Dec 31, 2024 | |
|---|---|---|
| Cash and cash equivalents | $90,465 | $55,155 |
| Accounts receivable, net | $23,737 | $5,580 |
| Inventories | $6,735 | $6,574 |
| Prepaid expenses and other current assets | $5,500 | $1,454 |
| Total current assets | $126,437 | $68,763 |
| Property, plant and equipment, net | $9,680 | $17,481 |
| Operating lease right-of-use assets, net | $19,518 | $33,512 |
| Brighton | $2,200 | |
| Other assets | $1,256 | $1,369 |
| Total assets | $156,891 | $121,125 |
| Accounts payable | $6,700 | $7,424 |
| Accrued and other current liabilities | $3,666 | $4,832 |
| Deferred revenue | $100 | $1,638 |
| Deferred grant | $2,738 | |
| Operating lease liabilities | $4,665 | $3,316 |
| Total current liabilities | $17,869 | $17,210 |
| Operating lease liabilities | $35,207 | $34,443 |
| Total liabilities | $53,076 | $51,653 |
| Commitments and contingencies (Note 10) | ||
| Preferred stock; $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding | ||
| Common stock; $0.0001 par value; 950,000,000 shares authorized; 134,536,592 and 116,934,314 shares issued and outstanding at December 31, 2025 and 2024, respectively | $13 | $12 |
| Additional paid-in capital | $322,156 | $243,794 |
| Accumulated other comprehensive income | $4 | |
| Accumulated deficit | $(218,358) | $(174,334) |
| Total stockholders’ equity | $103,815 | $69,472 |
| Total liabilities and stockholders’ equity | $156,891 | $121,125 |
Cash Flow
Consolidated Statement of Cash Flows
AMPRIUS TECHNOLOGIES, INC. (AMPX.W)
Year Ended (In thousands, except shares and per share data)
| Dec 31, 2025 | Dec 31, 2024 | |
|---|---|---|
| Net loss | $(44,024) | $(44,671) |
| Stock-based compensation | $7,410 | $7,343 |
| Depreciation and amortization | $4,366 | $3,808 |
| Amortization of deferred costs | $1,246 | |
| Non-cash operating lease expense | $5,143 | $5,143 |
| Impairment and other | $22,524 | $1,862 |
| Other non-cash items | $454 | |
| Accounts receivable, net | $(18,609) | $(4,315) |
| Inventories | $(161) | $(5,844) |
| Deferred costs | $(467) | |
| Prepaid expenses and other current assets | $(3,846) | $533 |
| Other assets | $28 | $(17) |
| Accounts payable | $(998) | $5,884 |
| Accrued and other current liabilities | $(1,170) | $(747) |
| Deferred revenue | $(1,538) | $(1,796) |
| Deferred grant | $2,738 | |
| Operating lease liabilities | $(3,451) | $(1,314) |
| Net cash used in operating activities | $(31,134) | $(33,352) |
| Purchase of property, plant and equipment | $(4,400) | $(3,207) |
| Net cash used in investing activities | $(4,400) | $(3,207) |
| Proceeds from issuance of common stock in connection with the At Market Issuance Sales Agreement, net | $63,668 | $33,416 |
| Sales Agreement | $63,668 | $33,416 |
| Proceeds from issuance of common stock upon exercise of stock warrants | $2,301 | $14,384 |
| Payment of equity financing costs | $(756) | |
| Proceeds from exercise of stock options | $5,071 | $109 |
| Net cash provided by financing activities | $71,040 | $47,153 |
| Net increase in cash, cash equivalents and restricted cash equivalents | $35,506 | $10,594 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | $4 | |
| Total cash, cash equivalents and restricted cash equivalents | ||
| Total cash, cash equivalents and restricted cash equivalents | ||
| Cash and cash equivalents | ||
| Restricted cash equivalents included in prepaid expenses and other current assets | ||
| Restricted cash equivalents included in other assets | ||
| Total cash, cash equivalents and restricted cash equivalents | ||
| Unpaid purchases of property, plant and equipment | $322 | $48 |
| Increase in fair value of modified stock warrants | $727 | |
| Cancellation and retirement of common stock | $1 |